moonshine <[EMAIL PROTECTED]> writes:
[EMAIL PROTECTED] wrote:
> [EMAIL PROTECTED] writes:
>
> NEW YORK, May 3 (Reuters) - Government scientists are excited about
> progress with tests on two cancer drugs that are eradicating any type of
> cancer in mice, the New York Times reported on Sunday.
>
> ["Government scientists," which Mac naturally confuses with "leaders in this
> field," seem to have been able to maintain their excitement for a very long
> time over this creeping breakthrough.
Naturally confuses? What's with that? The sources I used were not only "government
scientist's" . Sounds like your feeling's are hurt.
>
>
> A careful reader might have noted the following item at the end of the
> story:]
> Several companies are also working to develop the drugs, and both have been
> reported about extensively...
I never read the article your referring to. It's good to see others are making
headwayin
their research.
>
>
> [One of those companies seems further along in submitting a New Drug
> Application - specifically for lung cancer. Unfortunately for them they do
> not have the flaks that EntreMed (and Bristol Meyers) have.]
Shame on them. Maybe they should hire an experienced R&D man like yourself.
>
>
> [Making old news new - note the dates:]
>
> Endostatin, Newly Discovered Angiogenic Inhibitor Licensed
>
> ROCKVILLE, Md.�Dec. 5, 1996 -- EntreMed, Inc., announced today that it
> licensed the worldwide rights to the newly discovered angiogenesis
> inhibitor, Endostatin(TM), from Children's Hospital, a teaching affiliate of
> the Harvard Medical School in Boston, MA. EntreMed acquired these rights
> through an exclusive sponsored research agreement with Children's Hospital
> that supports the angiogenesis research of Dr. Judah Folkman and Resources
> his team of scientists.
What's your point. The work with these drugs have been going on for over a decade.My
post
had to do with the media report of a breaking story. I haven't seen nor heard anything
about these drugs before.
>
>
> {-]
> Antiangiogenic drugs have the potential to treat cancer as well as a variety of
> other angiogenic diseases such as blindness and arthritis...
>
> [Too bad they couldn't be working a bit harder on those illnesses with the
> new miracle drug but I guess one thing at a time.]
How do know somebody's not?
>
>
> At a recent Massachusetts Institute of Technology cancer research conference
> sponsored by the Whitehead Institute for Biomedical Research, Dr. Folkman
> announced that the combination of Endostatin(TM) and Angiostatin(TM), when
> used in preclinical studies to treat solid tumors for which there is no
> effective chemotherapy, prevented the reoccurrence of the tumors even months
> after cessation of the combined treatment. These findings from Drs. Michael
> O'Reilly and Judah Folkman, along with their research team, were recently
> cited in The Boston Globe (October 23, 1996), The Economist (November 16,
> 1996), and U.S. News & World Report (December 9, 1996).
>
> [Think maybe those other clowns were not colorful enough in their blurbs?]
What clowns are you talking about?
>
>
> [-]
> EntreMed Chairman, President and Chief Executive Officer Dr. John W.
> Holaday: "...we are extending our significant efforts to accelerate the
> availability of angiogenesis products for the treatment of cancer,
> blindness, and other diseases that depend on new blood vessel growth."
Seems like a good thing.
>
>
> [Damn. Arthritis just became "other diseases." But at least there is
> better hope for the vision challenged.]
Selective in your editing I see. Nice try Terry...At least your starting to show a
resemblance of a backbone. For awhile there I thought you were spineless. Bravo!!...Mac
Subscribe/Unsubscribe, email: [EMAIL PROTECTED]
In the body of the message enter: subscribe/unsubscribe law-issues
